Login to Your Account


CBMG taking China's stem cell industry to an international stage

By Shannon Ellis
Staff Writer

Wednesday, July 23, 2014

SHANGHAI – Cellular Biomedicine Group Inc. (CBMG), of Shanghai, has had a busy month, successfully listing on Nasdaq as the first "pureplay" biotech company from China and closing a $10 million stock transaction.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription